Shipman WD, Singh K, Cohen JM, Leventhal J, et al. Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment. Br J Dermatol 2023;189:339-341.
PMID: 37140007